GPT and breast cancer: Four (2.3%) patients in the “continued SDZ ETN” group (benign breast neoplasm, genitourinary tract neoplasm, pneumonia, cystitis hemorrhagic; 1 patient [0.6%] each) and 4 (2.4%) patients in the “switched to SDZ ETN” group (breast cancer, injection site reaction and alanine aminotransferase increase, acute cholecystitis, skin hyperpigmentation; 1 patient [0.6%] each) discontinued due to TEAEs.